# Phase 1 breast cancer trials recruiting: 188 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 188 trials in phase 1 for breast cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 breast cancer trials: 188 rows for $9.40, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/breast-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 188
- Recruiting or not yet: 188
- Read on: November 19, 2026

## Trials

The 25 newest of 188, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07928479 | Neoadjuvant Trastuzumab, Pertuzumab and Zongertinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-5 Study | The Netherlands Cancer Institute | Phase 1 | Not yet recruiting | HER2-positive Breast Cancer, Early Breast Cancer (EBC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928479) |
| November 6, 2026 | NCT07923214 | A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors | Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumors, Breast Cancer, Ovarian Cancer, Gastric Cancer, Other Solid Tumors | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923214) |
| November 4, 2026 | NCT07915297 | Safety and Biodistribution of \[68Ga\]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC) | Luminance Biosciences Inc | Phase 1 | Not yet recruiting | Metastatic Breast Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915297) |
| October 29, 2026 | NCT07905001 | A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer | Prelude Therapeutics Incorporated | Phase 1 | Recruiting | Breast Cancer, Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, HR-positive Breast Cancer... | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905001) |
| October 28, 2026 | NCT07899892 | A Study of 68Ga-FAPI Breast PET/MRI Scans in People With Breast Cancer | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Breast Cancer, Invasive Breast Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899892) |
| October 27, 2026 | NCT07897721 | A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors | Pfizer | Phase 1 | Not yet recruiting | Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Metastatic... | 268 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897721) |
| October 26, 2026 | NCT07894874 | A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors. | InventisBio Yiqi Beijing Limited | Phase 1 | Not yet recruiting | Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894874) |
| October 15, 2026 | NCT07876596 | A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080 | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Breast Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876596) |
| October 9, 2026 | NCT07867262 | A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally... | Genentech, Inc. | Phase 1 | Not yet recruiting | Advanced or Metastatic Breast Cancer | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867262) |
| October 6, 2026 | NCT07861139 | Comparative Study of QL1209 and Perjeta® in Healthy Male Participants | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Breast Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861139) |
| September 24, 2026 | NCT07838649 | Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity | Washington University School of Medicine | Phase 1 | Not yet recruiting | Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma, Hodgkin Lymphoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838649) |
| September 8, 2026 | NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | Sutro Biopharma, Inc. | Phase 1 | Recruiting | Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Colorectal Cancer... | 285 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807345) |
| September 3, 2026 | NCT07801508 | A Study of \[68Ga\]Ga-DWJ155 in Adult Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer, Triple-negative Breast Cancer, Advanced Non-small... | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801508) |
| August 7, 2026 | NCT07753226 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Breast Cancer, Solid Tumor | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753226) |
| July 15, 2026 | NCT07705334 | A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors | SHY Therapeutics | Phase 1 | Recruiting | Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705334) |
| June 22, 2026 | NCT07661641 | A Study of \[177Lu\]Lu-A9-0631 and \[225Ac\]Ac-A9-0642 With \[68Ga\]Ga-A9-6217 or \[177Lu\]Lu-A9-0631 Imaging in GRPR+ Solid Tumors | Alpha-9 Oncology USA Inc. | Phase 1 | Recruiting | Breast Cancer, Prostate Cancer, Colorectal Cancer, GRPR-positive Solid Tumors | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07661641) |
| June 22, 2026 | NCT07660055 | Study of \[177Lu\]Lu-DWJ155 and \[68Ga\]Ga-DWJ155 in Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660055) |
| June 17, 2026 | NCT07652242 | Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer | Immunomic Therapeutics, Inc. | Phase 1 | Recruiting | Triple Negative Breast Cancer (TNBC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652242) |
| June 12, 2026 | NCT07646106 | THE-0504 in Patients With Solid Tumors | Thena Biotech S.r.l. | Phase 1 | Recruiting | Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Gastric Cancer (GC), Triple -Negative Breast Cancer... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07646106) |
| June 9, 2026 | NCT07635277 | Akkermansia Muciniphila (AKK) for Radiation-Induced Skin Injury | West China Hospital | Phase 1 | Recruiting | Radiation-Induced Skin Injury | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07635277) |
| June 5, 2026 | NCT07630961 | Phase I Study of JFI447 \[68Ga\]Ga-DFC413 and Comparison to FFG233 \[68Ga\]Ga-NNS309 in Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), HR+/HER2- Ductal Breast Cancer... | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630961) |
| June 3, 2026 | NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | Huahui Health | Phase 1 | Recruiting | Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell... | 299 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623369) |
| May 22, 2026 | NCT07601620 | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early... | Shanghai Henlius Biotech | Phase 1 | Not yet recruiting | HER2 + Breast Cancer | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601620) |
| May 18, 2026 | NCT07593820 | A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics... | Vall d'Hebron Institute of Oncology | Phase 1 | Recruiting | Metastatic Gastric Cancer, Metastatic Breast Cancer, Endometrial Cancer Metastatic | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07593820) |
| May 12, 2026 | NCT07580833 | A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With... | Health Hope Pharma | Phase 1 | Not yet recruiting | Metastatic Breast Cancer | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07580833) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 7 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 6 |
| M.D. Anderson Cancer Center | 5 |
| Memorial Sloan Kettering Cancer Center | 5 |
| National Cancer Institute (NCI) | 4 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 4 |
| Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | 3 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 3 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 3 |
| Regor Pharmaceuticals Inc. | 2 |
| Baylor College of Medicine | 2 |
| University of Southern California | 2 |
| The Netherlands Cancer Institute | 2 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 2 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| SystImmune Inc. | 2 |
| Washington University School of Medicine | 2 |
| Myeloid Therapeutics | 2 |
| NiKang Therapeutics, Inc. | 2 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 2 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 2 |
| MOMA Therapeutics | 1 |
| Radiopharm Theranostics, Ltd | 1 |
| IntoCell, Inc | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 116 |
| China | 46 |
| Australia | 26 |
| Spain | 19 |
| Japan | 13 |
| France | 12 |
| South Korea | 10 |
| Canada | 10 |
| Italy | 8 |
| United Kingdom | 7 |
| Germany | 7 |
| Netherlands | 6 |
| Israel | 4 |
| Puerto Rico | 3 |
| New Zealand | 3 |
| Brazil | 2 |
| Singapore | 2 |
| Belgium | 2 |
| Denmark | 2 |
| Taiwan | 2 |
| Serbia | 1 |
| Georgia | 1 |
| Malaysia | 1 |
| Moldova | 1 |
| Thailand | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Educational research institutes in the United States](https://specstream.ai/data/businesses/educational-research-institutes/united-states)
- [Appliance repair companies in the United States](https://specstream.ai/data/businesses/appliance-repair-companies/united-states)
- [Psychology practices in the United States](https://specstream.ai/data/businesses/psychology-practices/united-states)
- [Hydraulic equipment suppliers in the United States](https://specstream.ai/data/businesses/hydraulic-equipment-suppliers/united-states)
- [Chiropractic clinics in the United States](https://specstream.ai/data/businesses/chiropractic-clinics/united-states)
- [Trucking companies in the United States](https://specstream.ai/data/businesses/trucking-companies/united-states)
